Fgfr4 Knockout Mouse Model for Respiratory System Studies
Posted Apr 19 2012 12:00am
Description of Invention: FGFR4 knockout: Lung alveoli fail to develop normally in double mutant with FGFR4 and FGFR3 knockouts.
The fibroblast growth factor receptor 4 (fgfr-4) gene was inactivated by targeted disruption and homozygous recombination to study its possible role in lung development. FGFR-4 is expressed in postnatal lung, and FGFR-4 null mice have no obvious abnormalities. However, mice that are doubly homozygous for targeted disruptions of FGFR3 and FGFR4 display novel phenotypes, including pronounced dwarfism and lung abnormalities. The lungs of the double knockout mice are normal at birth, but they fail to develop secondary septae that delimit alveoli and increase the surface area of the lung. Although lung function is impaired, the double homozygous knockout mice are viable but sickly.
Applications: Model for the study of respiratory system and potential treatments.
Development Status: Pre-clinical
Inventors: Chuxia Deng (NIDDK)
Patent Status: HHS Reference No. E-125-2000/0 – Research Tool. Patent protection is not being pursued for this technology.
For Licensing Information Please Contact: Charlene Sydnor Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4689 Fax: 301-402-0220